Bristol-Myers Squibb Given New $50.00 Price Target at Jefferies Group (BMY)
Stock analysts at Jefferies Group increased their price objective on shares of Bristol-Myers Squibb (NYSE:BMY) from $48.00 to $50.00 in a report issued on Thursday, Analyst Ratings.Net reports. The firm currently has a “hold” rating on the stock. Jefferies Group’s price objective indicates a potential downside of 9.14% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Credit Suisse reiterated an “outperform” rating on shares of Bristol-Myers Squibb in a research note to investors on Friday, December 20th. They now have a $60.00 price target on the stock, up previously from $56.00. Separately, analysts at UBS AG raised their price target on shares of Bristol-Myers Squibb from $48.00 to $54.00 in a research note to investors on Friday, December 20th. They now have a “neutral” rating on the stock. Finally, analysts at TheStreet reiterated a “buy” rating on shares of Bristol-Myers Squibb in a research note to investors on Monday, December 2nd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $51.43.
Bristol-Myers Squibb (NYSE:BMY) traded up 3.01% on Thursday, hitting $55.03. The stock had a trading volume of 10,360,412 shares. Bristol-Myers Squibb has a 52 week low of $33.69 and a 52 week high of $54.49. The stock has a 50-day moving average of $52.12 and a 200-day moving average of $47.54. The company has a market cap of $90.609 billion and a price-to-earnings ratio of 32.06.
Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Wednesday, October 23rd. The company reported $0.46 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.44 by $0.02. The company had revenue of $4.07 billion for the quarter, compared to the consensus estimate of $4.02 billion. During the same quarter last year, the company posted $0.41 earnings per share. Bristol-Myers Squibb’s revenue was up 8.8% compared to the same quarter last year. On average, analysts predict that Bristol-Myers Squibb will post $1.75 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Monday, February 3rd. Stockholders of record on Friday, January 3rd will be given a dividend of 0.36 per share. This represents a $1.44 dividend on an annualized basis and a yield of 2.62%. The ex-dividend date of this dividend is Tuesday, December 31st. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.35.
Bristol-Myers Squibb Company (NYSE:BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.